A Two-stage, Randomized, Double-blind, Dose Ranging Phase 2 Trial in Healthy Adult Participants to Investigate Optimal Dose and Dosing Regimen, and to Evaluate Safety and Immunogenicity of the Recombinant MVA-BN-WEV Vaccine
Latest Information Update: 02 Apr 2025
At a glance
- Drugs MVA-BN WEV (Primary)
- Indications Viral infections
- Focus Therapeutic Use
- Sponsors Bavarian Nordic
Most Recent Events
- 30 Mar 2025 Status changed from planning to recruiting.
- 26 Dec 2022 New trial record
- 23 Dec 2022 According to Bavarian Nordic media release, company announced a new agreement with the U.S. Department of Defenses (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), new agreement has a total value up to USD 83 million, of which the secured base agreement of USD 55 million covers the costs for this trial.